Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Martin Filipits(University of Vienna), Richard Greil(Paracelsus Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Sabine Pöstlberger(Paracelsus Medical University), Christine Gruber(Central Institution for Meteorology and Geodynamics), Peter Dubsky(Hirslanden Klinik St. Anna), Zerina Jasarevic(Paracelsus Medical University), A. Haid(Paracelsus Medical University), Gerhard Böhm(Paracelsus Medical University), Ralf Kemmerling(Paracelsus Medical University), Andrea Jelen(Paracelsus Medical University), R. Jakesz(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 16
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k